Durch Arbeiten im Rechenzentrum kann die Erreichbarkeit am 20. und 21. April 2024 kurzfristig eingeschränkt sein.
Download
journal.pone.0035421.PDF 1,26MB
WeightNameValue
1000 Titel
  • Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
1000 Autor/in
  1. Tseng, Chien-Te |
  2. Sbrana, Elena |
  3. Iwata-Yoshikawa, Naoko |
  4. Newman, Patrick C. |
  5. Garron, Tania |
  6. Atmar, Robert L. |
  7. Peters, Clarence J. |
  8. Couch, Robert B. |
1000 Erscheinungsjahr 2012
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2012-04-20
1000 Erschienen in
1000 Quellenangabe
  • 7(4):e35421
1000 Copyrightjahr
  • 2012
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0035421 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/ |
1000 Ergänzendes Material
  • https://doi.org/10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease. DESIGN: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology. RESULTS: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence. CONCLUSIONS: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Alumni
lokal Vaccines
lokal Mouse models
lokal SARS coronavirus
lokal Eosinophils
lokal Viral vaccines
lokal Antibodies
lokal Immunopathology
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VHNlbmcsIENoaWVuLVRl|https://frl.publisso.de/adhoc/uri/U2JyYW5hLCBFbGVuYQ==|https://frl.publisso.de/adhoc/uri/SXdhdGEtWW9zaGlrYXdhLCBOYW9rbw==|https://frl.publisso.de/adhoc/uri/TmV3bWFuLCBQYXRyaWNrIEMu|https://frl.publisso.de/adhoc/uri/R2Fycm9uLCBUYW5pYQ==|https://frl.publisso.de/adhoc/uri/QXRtYXIsIFJvYmVydCBMLg==|https://frl.publisso.de/adhoc/uri/UGV0ZXJzLCBDbGFyZW5jZSBKLg==|https://frl.publisso.de/adhoc/uri/Q291Y2gsIFJvYmVydCBCLg==
1000 Label
1000 Förderer
  1. National Institute of Allergy and Infectious Diseases |
1000 Fördernummer
  1. NO1 AI 30039
1000 Förderprogramm
  1. Public Health Service
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institute of Allergy and Infectious Diseases |
    1000 Förderprogramm Public Health Service
    1000 Fördernummer NO1 AI 30039
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6420343.rdf
1000 Erstellt am 2020-04-22T15:07:17.239+0200
1000 Erstellt von 122
1000 beschreibt frl:6420343
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Wed Apr 22 15:08:30 CEST 2020
1000 Objekt bearb. Wed Apr 22 15:08:17 CEST 2020
1000 Vgl. frl:6420343
1000 Oai Id
  1. oai:frl.publisso.de:frl:6420343 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source